Adaptive Biotechnologies Corporation(ADPT)

$25.25—

Chart

Adaptive Biotechnologies Corporation(ADPT)

NASDAQ

$25.25—

Chart Studio

ADPT(ADPT)

ADPT

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.10

Nov 4, 2026 · Reports after close

Revenue Estimate

$72M

FY2028E EPS$0.04

FY2029E EPS$0.23

Analyst Sentiment

Wall St. Consensus

Buy

17 analysts·Moderate coverage

Score

11 Buy (65%)4 Hold (24%)2 Sell (11%)

Rating Breakdown

Strong Buy

00%

Buy

1165%

Hold

424%

Sell

212%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$20.00

-20.8%

Consensus

$25.00

-1.0%

Bull

$27.50

+8.9%

12-Month Target Range17 analysts

$20.00$25.00$27.50

Current $25.25Consensus

Current Price

$25.25

Above Consensus

$0.25

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+22.22%

EPS—

FY2028

Rev+22.14%

EPS—

FY2029

Rev+24.76%

EPS+475.00%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$292M	$357M	$436M	$545M	$676M
Low	$284M	$348M	$405M	$524M	$651M
High	$297M	$366M	$452M	$557M	$692M
EBITDA Avg	$-221M	$-270M	$-329M	$-411M	$-510M
Low	$-224M	$-276M	$-341M	$-420M	$-522M
High	$-215M	$-263M	$-306M	$-395M	$-491M
EBIT Avg	$-234M	$-286M	$-349M	$-436M	$-541M
Low	$-237M	$-292M	$-362M	$-446M	$-553M
High	$-227M	$-278M	$-324M	$-419M	$-520M
Net Income Avg	$-85M	$-29M	$227,440	$35M	$8M
Low	$-91M	$-35M	$-59M	$33M	$7M
High	$-68M	$-20M	$47M	$36M	$8M
EPS Avg	$-0.55	$-0.18	$0.04	$0.23	$0.05
Low	$-0.60	$-0.23	$-0.39	$0.22	$0.05
High	$-0.45	$-0.13	$0.31	$0.24	$0.05
Analysts (Rev / EPS)	7 / 6	7 / 6	5 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$71M	$79M	$78M	$88M	$90M	$100M	$94M	$101M
Low	$68M	$78M	$76M	$86M	$87M	$98M	$91M	$98M
High	$73M	$82M	$81M	$91M	$93M	$104M	$97M	$105M
EBITDA Avg	$-54M	$-60M	$-59M	$-66M	$-68M	$-76M	$-71M	$-76M
Low	$-55M	$-62M	$-61M	$-69M	$-70M	$-78M	$-73M	$-79M
High	$-51M	$-59M	$-57M	$-65M	$-66M	$-74M	$-69M	$-74M
EBIT Avg	$-57M	$-63M	$-63M	$-70M	$-72M	$-80M	$-75M	$-81M
Low	$-58M	$-66M	$-65M	$-73M	$-74M	$-83M	$-77M	$-84M
High	$-54M	$-62M	$-61M	$-68M	$-70M	$-78M	$-73M	$-79M
Net Income Avg	$-14M	$-10M	$-15M	$-8M	$-8M	$-2M	$2M	$-2M
Low	$-15M	$-12M	$-15M	$-9M	$-8M	$-2M	$2M	$-2M
High	$-14M	$-7M	$-14M	$-8M	$-7M	$-2M	$2M	$-2M
EPS Avg	$-0.09	$-0.07	$-0.09	$-0.05	$-0.05	$-0.01	$0.01	$-0.01
Low	$-0.09	$-0.07	$-0.10	$-0.06	$-0.05	$-0.01	$0.01	$-0.01
High	$-0.09	$-0.05	$-0.09	$-0.05	$-0.05	$-0.01	$0.01	$-0.01
Analysts (Rev / EPS)	6 / 5	6 / 5	3 / 3	3 / 3	3 / 3	3 / 3	4 / 4	4 / 4

Earnings Surprises

Recent Analyst Actions

Aug 4, 2026Piper Sandler

Adaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler

Target:$27.50

+19.0%from $23.11

Jul 30, 2026Guggenheim

Adaptive Biotechnologies price target raised to $25 from $22 at Guggenheim

Target:$25.00

+10.8%from $22.56

Jul 30, 2026BTIG

Adeptus Biotechnologies Corp. (ADPT) PT Raised to $25 at BTIG

Target:$25.00

+10.8%from $22.56

Jul 9, 2026Morgan Stanley

Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley

Target:$20.00

-0.8%from $20.16

Jun 29, 2026Guggenheim

Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim

Target:$22.00

+5.0%from $20.96

Feb 6, 2026BTIG

Adaptive Biotechnologies price target raised to $22 from $21 at BTIG

Target:$22.00

+33.6%from $16.47

Feb 6, 2026Piper Sandler

Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan

Target:$21.00

+27.5%from $16.47

Jan 26, 2026Guggenheim

Adaptive Biotechnologies price target raised to $21 from $20 at Guggenheim

Target:$21.00

+11.1%from $18.91

Dec 1, 2025Morgan Stanley

Adaptive Biotechnologies assumed with an Equal Weight at Morgan Stanley

Target:$21.00

+11.5%from $18.84

Oct 15, 2025Piper Sandler

Adaptive Biotechnologies price target raised to $20 from $15 at Piper Sandler

Target:$20.00

+22.9%from $16.28

Sep 30, 2025Guggenheim

Guggenheim starts Adaptive with Buy on cancer test leadership

Target:$20.00

+48.6%from $13.46

Apr 4, 2024BTIG

Adeptus Biotechnologies Corp. (ADPT) PT Lowered to $5 at BTIG, 'assign a lower valuation to the businesses'

Target:$5.00

+86.6%from $2.68

Dec 21, 2022Piper Sandler

Adaptive Biotechnologies upgraded to Overweight from Neutral at Piper Sandler

Target:$14.00

+97.5%from $7.09

Aug 17, 2022Piper Sandler

Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler

Target:$12.00

+3.9%from $11.55

Jun 13, 2022Piper Sandler

Adaptive Biotechnologies (ADPT) Stock Price: $7.50 Target From Piper Sandler

Target:$7.50

+7.6%from $6.97

May 6, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18

Target:$18.00

+120.9%from $8.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance